This site is intended for UK healthcare professionals only

NEWS

 

Keep up to date with the latest news on bladder health, management and treatment.

Have you got a story to share? Email the team today.

Image of doctors walking relating to the article: People with advanced or metastatic urothelial cancer to get life-extending treatment
30 September 2021
Cancer
People with advanced or metastatic urothelial cancer to get life-extending treatment
NICE have recommended a new life-extending treatment as an option for untreated locally advanced or metastatic urothelial cancer.

Atezolizumab (also known as Tecentriq and made by Roche) has been recommended within its marketing authorisation for people whose tumour expresses PD-L1 at a level of 5% of more and when platinum-containing chemotherapy is unsuitable.

The recommendation comes after additional clinical evidence was collected as part the Cancer Drugs Fund managed access agreement.

Around 130 people per year will be eligible for treatment with atezolizumab.

The clinical trial shows that people who have atezolizumab are likely to live up to 8 months longer than those who have platinum-containing chemotherapy.

Atezolizumab meets NICE’s criteria to be considered a life-extending treatment at the end of life. The cost-effectiveness estimates are likely to be within what NICE considers an acceptable use of NHS resources.

Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE said: “I am pleased we are able to recommend this life-extending treatment for people with this form of urothelial cancer. The independent appraisal committee heard from the clinical and patient experts that there is an unmet clinical need for people with this form of cancer. They also recognised that people value additional treatment options which have a positive impact not just in terms of extending their life, but in improving their quality of life too.

“Today’s decision comes after additional clinical evidence was collected as part of a managed access agreement through the Cancer Drugs Fund. I am pleased we were able to not only secure access for people with this form of urothelial cancer in the interim but to now recommend it for routine use in the NHS.”

Read more news by the Bladder Interest Group here.

Latest News

Luja™ shows significant improvement in bladder emptying

Study results show that Coloplast’s new intermittent male catheter with 80+ micro-holes, Luja, achieved complete bladder emptying in one free flow* in 90% of catheterisations. Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male...

Artificial Intelligence used in bladder cancer treatment assessment

A computerised artificial intelligence (AI)-based decision support system (CDSS-T) enhanced the performance of clinicians when assessing patients’ response to chemotherapy prior to radical cystectomy, according to results from a small multi-institutional observer...

New treatment for urothelial cancer approved by NICE

Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment for urothelial cancer – avelumab – following its recommendation for routine NHS funding in final draft guidance published NICE. The recommendation for this...